Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FJXH8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,747
Award facts
- Contract value 100% obligated
- $1,747.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $1,747.44 delivery order to DMS Pharmaceutical Group Inc. on April 20, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for XOLAIR 300 MG/2 ML AUTOINJECT 2ML.
DMS Pharmaceutical Group Inc. is a woman-owned small business. Place of performance is Park Ridge, IL. The order ultimate completion date is May 11, 2026.
Quick answers
Who was awarded contract SPE2DR26FJXH8?
SPE2DR26FJXH8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on April 20, 2026.
How much is contract SPE2DR26FJXH8 worth?
The government has obligated $1,747 on SPE2DR26FJXH8.
Is contract SPE2DR26FJXH8 an order under another contract?
Yes. SPE2DR26FJXH8 is a delivery order under SPE2DR25D9307, an indefinite delivery contract.
Was contract SPE2DR26FJXH8 competed?
The extent of competition for SPE2DR26FJXH8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award